Abstracts Archive - Page 42 of 2616 - ACR Meeting Abstracts

Abstract Number: 0493 • ACR Convergence 2025
Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor
Maarten Kraan¹, Salah Hadi², Leonie Middelink³, Renato Chirivi³, Eric meldrum³, Naomi Klarenbeek⁴ and Patrick Round³, ¹Citryll BV, Den Dolder, Netherlands, ²ICON Netherlands BV, Groningen, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Trap (NET) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases including rheumatoid arthritis (RA). We report data of…
Abstract Number: 0530 • ACR Convergence 2025
Evaluating ChatGPT’s Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties
Annika Nack¹, Xabier Michelena Vegas², Pol Maymó-Paituvi³, Cristina Calomarde-Gómez⁴, david lobo⁵, Asier García-Alija⁶, Raquel Ugena-García⁴, Maria Aparicio¹, Paola Vidal Montal⁷ and Diego Benavent⁸, ¹Hospital Germans Trias i Pujol, Barcelona, Spain, ²Hospital Universitari Vall Hebron, Barcelona, Spain, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Doctor Josep Trueta University Hospital, Girona, Catalonia, Spain, ⁶Sant Pau Hospital, Barcelona, Catalonia, Spain, ⁷Bellvitge University Hospital, Barcelona, Spain, ⁸Hospital Universitari de Bellvitge, Madrid, Spain
Background/Purpose: Low back pain (LBP) is a multifactorial condition managed by various specialists. AI chatbots like ChatGPT may help clinicians identify probable diagnoses. Given that…
Abstract Number: 0517 • ACR Convergence 2025
Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
Qiguo Cui¹, Pan Wang², Bin Zhou¹ and QIn Huang³, ¹Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic), ²southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), ³Nanfang Hospital, Guangzhou, China (People's Republic)
Background/Purpose: Fatigue affects 70% of primary Sjögren's syndrome (pSS) patients, but its mechanisms remain unclear. We investigated clinical predictors and gut microbiota associations in pSS-related…
Abstract Number: 0357 • ACR Convergence 2025
Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM)
Jason Xenakis¹, Esther Yi¹, Iyar Mazar², Sarah Knight³, Harriet Makin³, Samantha Wratten³, Rohit Aggarwal⁴ and Stephanie McKee³, ¹Pfizer Inc., New York, United States of America, New York, ²Pfizer, US, New York, ³Clarivate, London, United Kingdom, ⁴University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Polymyositis (PM) is a subtype of idiopathic inflammatory myopathy (IIM) characterized by muscle inflammation and muscle weakness. Extra muscular manifestations like interstitial lung disease…
Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0531 • ACR Convergence 2025
Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
Anthony Marotta¹, Walter P. Maksymowych², Stephen Bleakley¹, Stephanie Wichuk³ and Norma Biln⁴, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Novel biomarkers for axSpA are urgently needed to enable earlier diagnosis and improve patient outcomes. An assay for quantifying 14-3-3η autoantibodies (AAbs) has been…
Abstract Number: 0502 • ACR Convergence 2025
Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Satani Sharkas¹, Saeed Abughazaleh² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Boston Medical Center - Brighton, Brighton, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are approved treatments for rheumatoid arthritis (RA). However, comparative safety data on cardiovascular outcomes and all-cause mortality…
Abstract Number: 0546 • ACR Convergence 2025
Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
Paras Karmacharya¹, Dilli Poudel², Daniel Shin³, Robert Fitzsimmons³, Leslie Crofford⁴ and Alexis Ogdie⁵, ¹Vanderbilt University, Nashville, TN, Hermitage, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³University of Pennsylvania, Philadelphia, ⁴Vanderbilt University Medical Center, Melbourne, AR, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Multimorbidity (≥ 2 chronic conditions) is common in inflammatory diseases such as psoriatic arthritis (PsA), psoriasis (PsO), and axial spondyloarthritis (AxSpA), increasing patient burden…
Abstract Number: 0735 • ACR Convergence 2025
A Real-World Study from the Greater Paris Clinical Data Warehouse
Aïcha Kante¹, Olivier Hassanaly², Geoffroy Peyrac³, David Saadoun⁴, Cacoub Patrice⁴, Alexis REGENT⁵, Benjamin Terrier⁶, Luc Mouthon⁷, Arsène Mekinian⁸, Karim Sacré⁹, Jean-François Alexandra¹⁰, Sébastien Abad¹¹, Robin Dhote¹¹, Cécile goujard¹², Damien Sène¹³, Stéphane Mouly¹⁴, Baptiste Hervier¹⁵, Olivier Bory¹⁶, Elisabeth Aslangul¹⁶, Isabelle Mahé¹⁶, Anne Couvelard¹⁷, Yann Nguyen¹⁸, Agnès Lefort¹⁸, Sophie georgin-Lavialle¹⁹, Olivier Steichen¹⁹, Viet-Thi Tran²⁰ and Cloé Comarmond¹, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Unité de recherche clinique, AP-HP, Hôpital Saint Louis, F⁷⁵⁰¹⁰, Paris, France, Paris, France, ³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ⁵Hopital Cochin, Paris, France, ⁶Cochin Hospital, Paris, France, ⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁹Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ¹⁰Internal Medicine, Hôpital Bichat, APHP, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP); Université Paris ¹³, Sorbonne Paris Cité, Bobigny, France, Bobigny, France, ¹²Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹⁴Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁵Internal Medicine Department, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France., Paris, France, ¹⁶Department of Internal Medicine, Louis-Mourier Hospital, AP-HP, Colombes, France, Colombes, France, ¹⁷Pathology Department, Bichat and Beaujon Hospitals, AP-HP, FHU MOSAIC, Université Paris Cité, Paris, France, Paris, France, ¹⁸Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAe, Centre for Research in Epidemiology and Statistics (CRESS), Paris; and Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, AP-HP, Paris, France, Paris, France
Background/Purpose: Giant cell arteritis (GCA) relapses are frequent and often require therapeutic intensification in the form of glucocorticoids (GC) increase. GCA management has significantly evolved…
Abstract Number: 0489 • ACR Convergence 2025
Efficacy and safety profile of JAK inhibitors in current practice in rheumatoid arthritis
Omar Al Tabaa¹, Salomé Abdellaoui¹, Sophie Hecquet¹, Marion Thomas², Sandrine Carves¹, Alice Combier¹, Olivier Fogel³, Yannick Allanore⁴ and Jérôme Avouac⁵, ¹Rheumatology department, Cochin Hospital, Paris, France, ²APHP, Paris, France, ³AP-HP, Paris, France, ⁴Université Paris Cité, Paris, France, ⁵Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: JAKi have been used in rheumatoid arthritis in current practice for several years now, with the progressive arrival on the market of 4 molecules.…
Abstract Number: 0548 • ACR Convergence 2025
Artificial Intelligence in Axial Spondyloarthritis Diagnosis: Integrating Structural and Inflammatory Lesionsfrom Sacrum MRI
Seonyoung Kang¹, Yunseo Kim², Seulkee Lee³, Myung Jin Chung⁴, Hyungjin Kim⁵, Jaejoon Lee⁴, Hakje Yoo⁶ and Hoon-Suk Cha⁴, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea, ²Samsung Medical Center, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea, ³Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea
Background/Purpose: The Assessment of SpondyloArthritis International Society (ASAS) criteria define positive MRI findings based on the presence of bone marrow edema (BME) in the sacroiliac…
Abstract Number: 0508 • ACR Convergence 2025
Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
Clementine Pouenat¹, Marine Vierling², Chiara Meier³, Ludivine Robin⁴, Philippe Kolb⁵, Hartmut Hengel⁶, Gaetane Nocturne⁷, Divi Cornec⁸, Valerie Devauchelle⁹, Véronique Le Guern¹⁰, Claire larroche¹¹, Damien Sène¹², Marion Couderc¹³, Eric HACHULLA¹⁴, Philippe Dieude¹⁵, Olivier Vittecoq¹⁶, Jacques Morel¹⁷, Nicolas Meyer¹⁸, Raphaele Seror¹⁹, Reinhard Voll²⁰, Pierre-Marie Duret²¹, Laurent Miguet²², Xavier Mariette²³ and Jacques-eric GOTTENBERG²⁴, ¹IBMC, UPR ³⁵⁷², STRASBOURG, France, ²Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France,, Strasbourg, Alsace, France, ³Strasbourg University Hospital, Department ofRheumatology, STRASBOURG, France, ⁴Strasbourg University Hospital, Department of pathology, ⁴CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France Strasbourg, France;, Strasbourg, Alsace, France, ⁵INSTITUTE OF VIROLOGY Medical Center, Freiburg, Freiburg, Germany, ⁶INSTITUTE OF VIROLOGY University Hospital Freiburg, FREIBURG, Germany, ⁷University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ⁸LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁹UBO, Brest, France, ¹⁰Cochin hospital, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne APHP, Bobigny, Paris, Ile-de-France, France, ¹²Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹³Service de Rhumatologie CHU Clermont-Ferrand, Clermont-Ferrand, ¹⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France, ¹⁵Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ¹⁶Service de Rhumatologie & CIC-CRB ¹⁴⁰⁴, CHU de Rouen, Université de Rouen, Rouen, Rouen, France, ¹⁷CHU and University of Montpellier, Montpellier, France, ¹⁸Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France, Strasbourg, Alsace, France, ¹⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²⁰University Medical Center Freiburg, Freiburg, Germany, ²¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²²Haemtology, Strasbourg University Hospital, IBMC UPR ³⁵⁷², Strasbourg, France, ²³Université Paris-Saclay, Le Kremlin Bicetre, France, ²⁴Hautepierre Hospital, STRASBOURG, Alsace, France
Background/Purpose: Fc‐gamma receptor (FcγR) activation by soluble IgG immune complexes (sICs) is considered to play a pivotal pathogenic role in B-cell-mediated autoimmune diseases, such as…
Abstract Number: 0753 • ACR Convergence 2025
Incidence of Ischemic Vision Loss Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Mary Peng¹, Kylie Carlson², Sebastian E Sattui³ and Michael Putman⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Ischemic vision loss affects up to one quarter of patients with giant cell arteritis (GCA). The incidence of ischemic vision loss among patients with…
Abstract Number: 0532 • ACR Convergence 2025
Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
Antonio Tonutti¹, Saverio D'Amico², Pierandrea Morandini², Cosimo Faeti², Elisa Barone¹, Nicoletta Luciano¹, Victor Savevski² and Carlo Selmi³, ¹Humanitas University, Pieve Emanuele, Italy, ²IRCCS Humanitas Research Hospital, Rozzano, Italy, ³Humanitas University, Milan, Italy
Background/Purpose: Distinguishing seronegative rheumatoid arthritis (RA) from psoriatic arthritis (PsA) sine psoriasis remains challenging, often relying on pathognomonic features (axial involvement, enthesitis) present in only…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].